Sinjard 10 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Empagliflozin |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus
- To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease
Pharmacology
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor that reduces renal absorption of glucose and results in increased glucose excretion, weight loss, and reduced blood pressure.
Dosage & Administration
Recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily.
Interactions
- Diuretics resulting in increased urine volume
- Insulin or insulin secretagogues increasing the risk for hypoglycemia
- Positive urine glucose test is not recommended
- Interference with 1,5-anhydroglucitol (1,5-AG) assay
Contraindications
Empagliflozin is contraindicated in patients with serious hypersensitivity reaction, severe renal impairment, end-stage renal disease, or dialysis.
Side Effects
- Urinary tract infections
- Female genital mycotic infections
- Dehydration
- Hypotension
- Weakness
- Dizziness
- Increased thirstiness
Pregnancy & Lactation
Not adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit justifies potential risk to the fetus. Not recommended when breastfeeding.
Precautions & Warnings
Assessment of renal function is recommended prior to initiation of Sinjard and periodically thereafter. Should not be initiated in patients with an eGFR less than 45 ml/min/1.73 m2.
Overdose Effects
Usual supportive measures should be employed in the event of an overdose. Removal of Sinjard by hemodialysis has not been studied.
Therapeutic Class
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.
Chemical Structure
- Molecular Formula: C23H27ClO7
- Chemical Structure Image: (link to image)
Common Questions about Sinjard 10 mg Tablet
- Used to improve glycemic control in adults
- May be unsafe to use during pregnancy
- Probably unsafe to use during breastfeeding
- Should be used cautiously in patients with an underlying kidney disease
- No dose adjustment needed for patients with mild to moderate liver disease
- Quick Tips